FDA OKs Roche’s Zelboraf for rare blood disease
US regulators have approved Roche’s Zelboraf (vemurafenib) for patients with a rare blood condition called Erdheim-Chester disease (ECD) carrying a mutation called BRAF V600
Read More
Tag: ECD
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
